for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GlaxoSmithKline plc (ADR)

GSK.N

Latest Trade

38.36USD

Change

0.58(+1.54%)

Volume

797,269

Today's Range

37.48

 - 

38.52

52 Week Range

31.43

 - 

48.25

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
37.78
Open
37.64
Volume
797,269
3M AVG Volume
100.60
Today's High
38.52
Today's Low
37.48
52 Week High
48.25
52 Week Low
31.43
Shares Out (MIL)
5,017.38
Market Cap (MIL)
94,999.64
Forward P/E
12.51
Dividend (Yield %)
5.35

Next Event

Q4 2020 GlaxoSmithKline PLC Earnings Release

Latest Developments

More

Immutep Says Ulcerative Colitis Phase II Study Of GSK2831781 Discontinued

Viiv Healthcare Announces FDA Approval Of Cabenuva For HIV Treatment

Biondvax Announces Appointment Of Amir Reichman As New CEO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About GlaxoSmithKline plc (ADR)

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

Industry

Major Drugs

Contact Info

G S K House, 980 Great West Road

TW8 9GS

United Kingdom

+44.20.80475000

https://www.gsk.com/

Executive Leadership

Jonathan Richard Symonds

Independent Non-Executive Chairman of the Board

Emma N. Walmsley

Chief Executive Officer, Executive Director

Iain James Mackay

Chief Financial Officer, Executive Director

Roger G. Connor

President - Vaccines

Brian McNamara

Chief Executive Officer - GSK Consumer Healthcare

Key Stats

2.00 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

38.9K

2018

41.1K

2019

43.1K

2020(E)

45.9K
EPS (USD)

2017

2.910

2018

3.104

2019

3.161

2020(E)

3.067
Price To Earnings (TTM)
11.03
Price To Sales (TTM)
2.03
Price To Book (MRQ)
4.91
Price To Cash Flow (TTM)
9.70
Total Debt To Equity (MRQ)
197.73
LT Debt To Equity (MRQ)
163.33
Return on Investment (TTM)
13.61
Return on Equity (TTM)
8.61

Latest News

Latest News

Factbox: Latest on worldwide spread of the coronavirus

U.S. President Joe Biden will sign orders to speed delivery of coronavirus stimulus checks and food aid, while Europe's vaccination drive was dealt another blow when AstraZeneca said initial deliveries to the region will fall short of the targeted volumes.

U.S. FDA approves GSK unit's long-acting HIV injection

The U.S. Food and Drug Administration on Thursday approved a long-acting HIV injection from British drugmaker GlaxoSmithKline's HIV treatment division, ViiV Healthcare.

Merck KGaA, GSK suffer lung cancer drug setback

Merck KGaA's drug development programme has suffered a setback with its most important experimental drug, cancer treatment bintrafusp alfa, failing early in its lead trial.

Merck KGaA stops lung cancer trial testing drug hopeful bintrafusp alfa

Germany's Merck KGaA said the most important clinical trial testing its cancer drug hopeful bintrafusp alfa, which it is co-developing with GlaxoSmithKline, would be stopped because the treatment does not appear to work.

FDA rejects GSK's request to weigh in on Zofran birth defect litigation

The U.S. Food and Drug Administration has rejected GlaxoSmithKline's request to weigh in on a key question in lawsuits by women who say the drugmaker failed to warn them that taking the anti-nausea drug Zofran during pregnancy can cause birth defects.

BRIEF-GSK, Novartis Announce Collaboration To Support Scientific Research Into Genetic Diversity In Africa

* GSK AND NOVARTIS ANNOUNCE COLLABORATION TO SUPPORT SCIENTIFIC RESEARCH INTO GENETIC DIVERSITY IN AFRICA

BRIEF-GSK Presents Positive Efficacy Data Of Dostarlimab In Mismatch Repair-Deficient (dMMR) Solid Cancers At ASCO Gastrointestinal Cancers Symposium

* GSK PRESENTS POSITIVE EFFICACY DATA OF DOSTARLIMAB IN MISMATCH REPAIR-DEFICIENT (DMMR) SOLID CANCERS AT ASCO GASTROINTESTINAL CANCERS SYMPOSIUM

BRIEF-GSK Says ViiV Healthcare Gets EU Marketing Nod For Dispersible-Tablet Formulation Of Dolutegravir, Tivicay

* GSK - VIIV HEALTHCARE RECEIVES EU MARKETING AUTHORISATION FOR FIRST-EVER DISPERSIBLE-TABLET FORMULATION OF DOLUTEGRAVIR, TIVICAY

GSK, Vir to test antibody for COVID-19 treatment

British drugmaker GSK and U.S.-based Vir Biotechnology will evaluate a second antibody-based treatment in patients with mild to moderate COVID-19 in an early- to mid-stage trial, the companies said on Tuesday.

BRIEF-GSK, Vir Biotechnology Announce Study To Evaluate Vir-7832 In Early Treatment Of COVID-19

* VIR BIOTECHNOLOGY AND GSK ANNOUNCE NHS-SUPPORTED AGILE STUDY TO EVALUATE VIR-7832 IN EARLY TREATMENT OF COVID-19

BRIEF-Eligo Bioscience Enters Into A Research And Option Agreement With Glaxosmithkline

* ELIGO BIOSCIENCE SA - ANNOUNCED THAT IT HAS ENTERED INTO A RESEARCH AND OPTION AGREEMENT WITH GLAXOSMITHKLINE Source text for Eikon: Further company coverage:

Judge finds economic injury, design defect claims preempted in Zantac MDL

A federal judge on Friday tossed a slew of claims against major drugmakers in multidistrict litigation over recalled heartburn drug Zantac, finding them preempted by the federal Food, Drug and Cosmetic Act.

Exclusive: Drugmakers to hike prices for 2021 as pandemic, political pressure put revenues at risk

Drugmakers including Pfizer Inc, Sanofi SA, and GlaxoSmithKline Plc plan to raise U.S. prices on more than 300 drugs in the United States on Jan. 1, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors.

EXCLUSIVE-Drugmakers to hike prices for 2021 as pandemic, political pressure put revenues at risk

Drugmakers including Pfizer Inc , Sanofi SA, and GlaxoSmithKline Plc plan to raise U.S. prices on more than 300 drugs in the United States on Jan. 1, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors.

BRIEF-GlaxoSmithKline Says ViiV First Long-Acting HIV Regimen Approved In EU

* GLAXOSMITHKLINE PLC - VIIV FIRST LONG-ACTING HIV REGIMEN APPROVED IN EU

Sosei, GSK agree to develop inflammatory bowel disease treatment

Japan's Sosei Group Corp said late on Sunday it agreed with GlaxoSmithKline to collaborate on developing treatments for some digestive tract illnesses caused by immune disorders.

BRIEF-GSK, Ahren Announce Co-Led Series A Investment In Adrestia

* GSK - GSK AND AHREN ANNOUNCE CO-LED SERIES A INVESTMENT IN ADRESTIA

Law, medicine profs throw support behind Teva's 'skinny label' appeal

Dozens of professors at major universities are urging the full Federal Circuit U.S. Court of Appeals to review an October panel decision that Teva Pharmaceutical Industries Ltd's generic version of GlaxoSmithKline PLC's heart drug Coreg infringed a GSK patent, even though...

Zofran plaintiffs say FDA's warning rejection does not moot cases

A lawyer for women suing GlaxoSmithKline for failing to warn that taking the anti-nausea drug Zofran during pregnancy can cause birth defects argued on Wednesday that the U.S. Food and Drug Administration's rejection of a warning label does not moot their cases.

Sanofi and GSK delay COVID-19 vaccine, marking setback for global fight

Sanofi and GlaxoSmithKline said clinical trials of their COVID-19 vaccine showed an insufficient immune response in older people, delaying its launch to late next year and marking a setback in the global fight against the pandemic.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up